Table 1:
Patient baseline characteristics
| Characteristic | Patients (%) n=76 |
|---|---|
| Sex − no. (%) | |
| Male | 36 (47%) |
| Female | 40 (53%) |
| Age − no. (%) | |
| Median | 56 |
| Range | 22–82 |
| Race − no. (%) | |
| White | 58 (76%) |
| Black/African American | 2 (2%) |
| Asian | 12 (16%) |
| Other/Unknown | 4 (5%) |
| Smoking History − no. (%) | |
| Current | 3 (4%) |
| Former | 26 (34%) |
| Never | 47 (62%) |
| No. of prior treatments − no. (%) | |
| 0 | 14 (18%) |
| 1 | 17 (22%) |
| 2 | 18 (24%) |
| 3 | 10 (13%) |
| ≥ 4 | 17 (22%) |
| Prior ALK TKI Treatment − no. (%) | |
| ALK TKI Naïve | 17 (22%) |
| Prior Crizotinib only | 37 (49%) |
| Prior Crizotinib and Ceritinib | 9 (12%) |
| Prior Crizotinib and Alectinib | 6 (8%) |
| Prior Crizotinib, Ceritinib, and Alectinib | 6 (8%) |
| Prior Crizotinib, Ceritinib, and Brigatinib | 1 (1%) |
no: number; ALK: anaplastic lymphoma kinase; TKI: tyrosine kinase inhibitor